Cannabis and its Derivatives

Dr. Rahul Shukla is currently working as an Assistant Professor (Contract) at Department of Pharmaceutics, NIPER Raebareli, India, He has a PhD in Pharmaceutical Sciences from CSIR CDRI and J.N.U New Delhi, India, an M.Pharm from IIT BHU,Varanasi, India and B.Pharm from Jamia Hamdard, New Delhi. He has more than ten years of research and academic experience with more than 30 publications and 10 book chapters to his credit. He has filed 7 Indian Patent and 1 Copyright. Recently he has edited a book on the Role of Novel Drug Delivery Vehicles in Nanobiomedicine. His current research interests include?targeted drug delivery systems, particle?engineering, controlled delivery?for neurodegenerative diseases,?dendrimer mediated drug delivery, solubilization and bioavailability enhancements. Mr. Mayank Handa, has completed his B. Pharm and M. Pharm from U.I.P.S, Panjab University, Chandigarh India. Currently, pursuing as Ph.D. at National Institute of Pharmaceutical Education and Research-Raebareli, Lucknow UP. His past industrial experience includes working at Eisai India Limited, India and Themis Medicare Limited, India. He has more than 20 peer reviewed publications in journals international repute and 10 book chapter. He has filed 5 Indian patent and 1 Copyright. His research interests in polymeric nanoparticles and emulsion based drug delivery, targeted drug delivery systems, Intranasal and transdermal drug delivery. Dhirendra Pratap Singh is currently a Scientist in Neurotoxicology and Immunotoxicology Laboratory of the ICMR-National Institute of Occupational Health, Ahmedabad, India. He earned PhD in Pharmaceutical Sciences from Panjab University in Chandigarh and worked as a research fellow at the DBT-National Agri-Food Biotechnology Institute (NABI) in Mohali during his PhD, focusing on "cobiotics," a specialized combination of prebiotics and antioxidants intended for food-based applications and gut microbial modification to improve metabolic health. After a brief period as a post-doctoral researcher at the University of Gothenburg in Sweden, he joined ICMR-NIOH in Ahmedabad as a Scientist. His current research interests include: i) host-gut microflora interactions in neurobehavioral aberrations related to heavy metal toxicity, ii) the development of cost-effective diagnostics for exposure to these metals, and iii) the environmental impact of pharmaceutical industry clusters on the emergence of antimicrobial resistance (AMR). He is an experienced experimental pharmacologist with a particular interest in environmental toxicology, focusing on both legacy and emerging endocrine disruptors, such as bisphenols and other plasticizers, often referred to as "forever chemicals."

Dr. Ashish Dhir is an Associate Principal Scientist in Drug Discovery for Merck in New Jersey. He was previously a Senior Scientist in the Department of Neurology, School of Medicine, University of California, Davis in Sacramento. He received his doctorate in Pharmacology from Panjab University, Chandigarh, India. He has over 15 years of experience in preclinical research in the field of neurological and neuropsychiatric disorders. Dr. Dhir's research entails establishing and validating animal models of various disease conditions, as well as investigating novel drugs and targets for disease treatment. Dr. Dhir has over 90 peer-reviewed journal papers and serves as an ad hoc reviewer and on the Editorial Board of several prestigious journals.?He was recently named to the list of the world's top 2% pharmacology scientists (ranking 1053 out of 94611). Dr. Dhir has received numerous honors, including the Rafaelsen Young Investigator Award from the Collegium International Neuropsychopharmacologicum (CINP).